Table 5.
N-glycans of adult patients
| CG patients (n = 17) | Controls (n = 79) | P-value | Main glycansa | |
|---|---|---|---|---|
| GPsb | ||||
| GP1c | 0.27 (0.23–0.39) | 0.66 (0.26–1.95) | <0.0005 | FA1 |
| GP3d | 1.04 (0.79–1.25) | 0.39 (0.22–0.57) | <0.0005 | A2B |
| GP5c | 0.15 (0.13–0.21) | 0.19 (0.01–0.26) | 0.001 | M5 |
| GP7d | 1.17 (0.58–1.44) | 0.52 (0.23–0.95) | <0.0005 | A2[3]G1 |
| GP15d | 0.15 (0.09–0.23) | 0.07 (0.00–20.25) | <0.0005 | FA2G2 |
| GP18c | 0.14 (0.09–0.18) | 0.42 (0.22–2.75) | <0.0005 | FA2G1S1 |
| GP21d | 0.27 (0.15–0.34) | 0.19 (0.10–11.50) | <0.0005 | A2BG2S1 |
| GP24c | 0.03 (0.01–0.05) | 0.06 (0.03–0.36) | <0.0005 | ? |
| GP26d | 0.20 (0.08–0.33) | 0.11 (0.04–0.70) | <0.0005 | A2BG2S2 |
| Glycan featuresa | ||||
| Bn | 1.57 (1.19–1.69) | 0.85 (0.44–22.50) | <0.0005 | Afucosylated neutral glycans |
Data reported in median and ranges. Only significant differences are shown.
a
Main glycans were assigned and N-glycan features calculated as described in Pucic et al. (2011).
b
The percentage areas of 28 IgG N-GPs, quantified as described in Stockmann et al. (2016).
cDecreased in CG patients (when compared with controls).
dIncreased in CG patients (when compared with controls).
Bn: afucosylated bisected neutral glycans; ?: unknown.